Abstract: Journal of Pharmaceutical Research International 32(8): 29-43, 2020; Article no.JPRI.56916 ISSN: 2456-9119 (Past name: British Journal of Pharmaceutical Research, Past ISSN: 2231-2919, NLM ID: 101631759) Optimizing the Use of Hydroxychloroquine in the Management of COVID-19 Given Its Pharmacological Profile Ahmed S. Ali1*, Mahran S. Abdel-Rahman2, Riyadh S. Almalikil3, Abir S. Mohamed4, Khalid A. Alfaifi5, Abdelbabgi El. Fadil6, Nagla A. El-Shitany7,8 and Huda M. Alkreathy1 1 Department of Pharmacology, Faculty of Medicine, King Abdulaziz University, KSA. 2 Department of Pharmacology, Faculty of Medicine, Assiut University, Egypt. 3 Department of Pharmacology, Faculty of Pharmacy, Umm Al-qura University, KSA. 4 Department of Internal Medicine, Faculty of Public Health and Tropical Medicine, Jazan University, KSA. 5 Department of Pharmacy, Medical Services Directorate, Taif, KSA. 6 Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, KSA. 7 Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, KSA. 8 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta, Egypt. Authors’ contributions All authors actively participated in this reference research and major work. Author ASA designed the idea in cooperation with author MSAR. Author RSA early joined the team to organize communication between researchers. He prepares the introduction. Author ASA assumed full supervision of the research with the assistance of all colleagues author MSAR prepared the side effects of the drug he also reviewed all that colleagues author ASM reviewed all clinical issues related to COVID 19 patients and their management she described in details cardiac toxicity of HCQ. Author AEF revised all sections related to the novel virus description and epidemiology. Author KAA collected and reviewed the pharmacokinetics of HCQ and its integration with the efficacy and safety issues. Author NAES participated actively in explaining the mechanism of HCQ. She also provided the summary and conclusion. Author HMA provided huge effort to edit the review, in a professional way regarding all aspects, language, reference and connoting ideas etc. Article Information DOI: 10.9734/JPRI/2020/v32i830468 Editor(s): (1) Dr. Jongwha Chang, University of Texas, USA. Reviewers: (1) Victor B. Oti, Nasarawa State University, Nigeria. (2) Pichon Maxime, University Hospital of Poitiers, France. (3) Celso Ramos, National Institute of Public Health, Mexico. Complete Peer review History: http://www.sdiarticle4.com/review-history/56916 Review Article Received 23 April 2020 Accepted 12 May 2020 Published 29 May 2020 _____________________________________________________________________________________________________ *Corresponding author: E-mail: Profahmedali@gmail.com; ORCID: 0000-0002-3341-8177 Ali et al.; JPRI, 32(8): 29-43, 2020; Article no.JPRI.56916 ABSTRACT After the global pandemic of the new coronavirus, its rapid spread and many victims, it is necessary to find an effective vaccine or drugs to overcome it. Most specialists consider that repositioning some medications is the best, fastest and most reliable option for treating patients with the new coronavirus without delay. One of these drugs was an old antimalarial drug, hydroxychloroquine. The current review aimed to explore its potential mechanism, as well as its pharmacokinetics and toxicity, in an attempt to suggest a..